Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: Results from a multicenter trial

Clinical Therapeutics

Volumn 25, Issue 6, 2003, Pages 1846-1871

  López, Horacio ^a   Li, Jim Z ^b   Balan, Dan A ^c   Willke, Richard J ^b   Rittenhouse, Brian E ^b   Mozaffari, Essy ^b   Vidal, Gabriela ^a   Zitto, Teresa ^a   Tang, Tom ^b  

^a Centro de Infectologia   (Argentina)

^b PFIZER INC   (United States)

^c WESTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

Cost minimization analysis; Gram positive infection; Length of stay; Linezolid; Mexico; South America; Teicoplanin

Indexed keywords

LINEZOLID; TEICOPLANIN;

ADOLESCENT; ADULT; AGE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BINDING SITE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; GRAM POSITIVE BACTERIUM; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTPATIENT; PHASE 3 CLINICAL TRIAL; RACE; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; SEPSIS; SOUTH AMERICA; STATISTICAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0038016792     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80173-X     Document Type: Article

References (53)

1. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis. 1999;29:239-244.
2. Sader H, Jones R. Resistencia a los antimicrobianos de los agentes patogenos causantes de infecciones nosocomiales y comunitarias en America Latina: Resena general de las estadisticas de 1997. In: Salvatierra González R, Benguigui Y, eds. Resistencia Antimicrobiana en las Americas: Magnitud del Problema y su Contencion. Washington, DC: Organización Panamericana de la Salud, Organización Mundial de Salud. 2000;54-73.
3. Weinstein RA. Nosocomial infection update. Emerg Infect Dis. 1998;4:416-420.
4. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med. 1999;20:303-316.
5. Solomon S, Horan T, Andrus M, et al. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control. 2002;30:458-475.
6. Casellas JM, Blanco MG, Pinto ME. The sleeping giant. Antimicrobial resistance. Infect Dis Clin North Am. 1994;8:29-45.
7. Goldberg M, Radice M, Couto E, et al. Bacterial frequency and resistance patterns in intensive care units (ICU) in Argentinean hospitals: Summary of 1996 through 1999. Results from SIR Antibiotic Surveillance Program. In: Program and Abstracts of the 40th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000. Washington, DC: American Society for Microbiology; 2000. Abstract 1029.
8. Bantar C, Famiglietti A, Goldberg M. Three-year surveillance study of nosocomial bacterial resistance in Argentina. The Antimicrobial Committee; and the National Surveillance Program (SIR) Participants Group. Int J Infect Dis. 2000;4:85-90.
9. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morbid Mortal Wkly Rep. 1997;46:813-815.
10. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morbid Mortal Wkly Rep. 1997;46:765-766.
11. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: Perspectives on measures needed for control. Ann Intern Med. 1996;124:329-334.
12. Tabaqchali S. Vancomycin-resistant Staphylococcus aureus: Apocalypse now? Lancet. 1997;350:1644-1645. Letter.
13. Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: Infection control considerations. Clin Infect Dis. 1998;27:245-249.
14. Waldvogel FA. New resistance in Staphylococcus aureus. N Engl J Med. 1999;340: 556-557.
15. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 1996;37:209-222.
16. Woodford N, Johnson AP, Morrison D, Speller DC. Current perspectives on glycopeptide resistance. Clin Microbiol Rev. 1995;8:585-615.
17. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40: 135-136.
18. Johnson AP, Uttley AH, Woodford N, George RC. Resistance to vancomycin and teicoplanin: An emerging clinical problem. Clin Microbiol Rev. 1990;3:280-291.
19. Clemett D, Markham A. Linezolid. Drugs. 2000;59:815-827.
20. Perry CM, Jarvis B. Linezolid: A review of its use in the management of serious gram-positive infections. Drugs. 2001;61:525-551.
21. Corti G, Cinelli R, Paradisi F. Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic. Int J Antimicrob Agents. 2000;16:527-530.
22. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408-3413.
23. Cammarata SK, Schueman LK, Timm JA, et al. Oral linezolid in the treatment of community-acquired pneumonia: A Phase III trial. In: Program and Abstracts of the American Thoracic Society Annual Meeting, 2000 (Toronto). New York: American Thoracic Society, 2000:654. Abstract E73.
24. Cammarata SK, Bermudez M, Golin V, et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized community-acquired pneumonia. In: Program and Abstracts of the 9th International Congress on Infectious Diseases; April 10, 2000; Buenos Aires, Argentina. Boston, Mass: International Society of Infectious Diseases; 2000:181. Abstract 80.008.
25. Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J. 2001;20:488-494.
26. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402-412.
27. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481-1490.
28. Wilcox M, Tang T, Hafkin B. Linezolid versus teicoplanin for the treatment of hospitalized patients with gram-positive infections. In: Program and Abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 22, 2001, Chicago, Illinois. Washington, DC: American Society for Microbiology; 2001. Abstract 1481.
29. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy. 1997;17:271-276.
30. Ramirez JA. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: Focus on switch therapy. Pharmacotherapy. 2001;21:79S-82S.
31. Cunha BA. Intravenous-to-oral antibiotic switch therapy. A cost-effective approach. Postgrad Med. 1997;101:111-123.
32. Conly JM, Low DE. Intravenous to oral antimicrobial stepdown therapy: Improving the quality of care and reducing costs. Can J Infect Dis. 1995;6(Suppl A):3A-5A.
33. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med. 1991;91:462-470.
34. Walters DJ, Solomkin JS, Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections. Pharmacoeconomics. 1999;16:551-561.
35. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother. 1995;29:561-565.
36. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial. Pharmacotherapy. 2001;21:263-274.
37. Willke RJ, Glick HA, Li JZ, Rittenhouse BE. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections: An application of multivariate survival analysis. Int J Technol Assess Health Care. 2002;18:540-554.
38. Targocid [package insert]. Strasbourg, France: Aventis; 2003.
39. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644-1655.
40. Hosmer DW Jr, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: Wiley; 1999.
41. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Vol 1. Berkeley, Calif: University of California Press; 1967;221-233.
42. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817-830.
43. Schulman K, Burke J, Drummond M, et al. Resource costing for multinational neurologic clinical trials: Methods and results. Health Econ. 1998;7:629-638.
44. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs? Infect Control Hosp Epidemiol. 1999;20:408-411.
45. File TM Jr. Overview of resistance in the 1990s. Chest. 1999;115(Suppl 3):3S-8S.
46. Lavin BS. Antibiotic cycling and marketing into the 21st century: A perspective from the pharmaceutical industry. Infect Control Hosp Epidemiol. 2000;21 (Suppl 1):S32-S35.
47. Barlow GD, Nathwani D. Sequential antibiotic therapy. Curr Opin Infect Dis. 2000;13: 599-607.
48. Davey P, Nathwani D. Sequential antibiotic therapy: The right patient, the right time and the right outcome. J Infect. 1998;37(Suppl 1):37-44.
49. Nathwani D. Sequential switch therapy for lower respiratory tract infections: A European perspective. Chest. 1998;113(Suppl 3):211S-218S.
50. Nathwani D, Malek M. Cost considerations in the evaluation of new therapies for gram-positive bacteria. Int J Antimicrob Agents. 1999;13:71-78.
51. Vinken A, Li Z, Balan D, et al. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: A decision analytical model. J Hosp Infect. 2001;49(Suppl A):S13-S24.
52. Lopez H, Zitto T, Vidal G. Modelo de evaluación farmacoeconómica de linezolid. Infectious Diseases in Clinical Practice en Español. 2002;Suppl:44-47.
53. Boyer JG, Pathak DS. Establishing value through pharmacoeconomics: The emerging third objective in clinical trials. Top Hosp Pharm Manag. 1994;13:1-10.